Following a record-breaking merger, one of the world’s biggest pharmaceutical brands wanted help with effective and timely clinical trial data ecosystem convergence.
With COVID-19 wreaking havoc and a challenging timeline to overcome, the pharma giant could not finalize an efficient synergy strategy that could help realize cost savings and ensure business continuity.
Brought on board to help, GEP helped the company drive synergy and save approximately 7% and 30% on annual licensing and annual managed services spend, respectively.
This case study reveals how GEP helped the company rework its governance to ensure long-term benefits. It’s a must-read for procurement professionals who want to understand or implement complex data ecosystem convergence in their organizations.
